CA2533752A1 - Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires - Google Patents

Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires Download PDF

Info

Publication number
CA2533752A1
CA2533752A1 CA002533752A CA2533752A CA2533752A1 CA 2533752 A1 CA2533752 A1 CA 2533752A1 CA 002533752 A CA002533752 A CA 002533752A CA 2533752 A CA2533752 A CA 2533752A CA 2533752 A1 CA2533752 A1 CA 2533752A1
Authority
CA
Canada
Prior art keywords
amino
quinazoline
methoxy
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533752A
Other languages
English (en)
Inventor
Birgit Jung
Hubert Pueschner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International Gmbh
Birgit Jung
Hubert Pueschner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Birgit Jung, Hubert Pueschner filed Critical Boehringer Ingelheim International Gmbh
Publication of CA2533752A1 publication Critical patent/CA2533752A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002533752A 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires Abandoned CA2533752A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10334226A DE10334226A1 (de) 2003-07-28 2003-07-28 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
DE10334226.5 2003-07-28
PCT/EP2004/008185 WO2005011701A1 (fr) 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires

Publications (1)

Publication Number Publication Date
CA2533752A1 true CA2533752A1 (fr) 2005-02-10

Family

ID=34071934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533752A Abandoned CA2533752A1 (fr) 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires

Country Status (5)

Country Link
EP (1) EP1651228A1 (fr)
JP (1) JP2007500156A (fr)
CA (1) CA2533752A1 (fr)
DE (1) DE10334226A1 (fr)
WO (1) WO2005011701A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009265A (es) * 2005-02-04 2007-09-07 Boehringer Ingelheim Int Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica.
TW200640904A (en) * 2005-02-26 2006-12-01 Astrazeneca Ab Quinazoline derivatives
TWI385174B (zh) 2008-11-10 2013-02-11 Nat Health Research Institutes 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
WO2017141271A1 (fr) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique stable d'afatinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10231711A1 (de) * 2002-07-13 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
DE10334226A1 (de) 2005-02-17
WO2005011701A1 (fr) 2005-02-10
EP1651228A1 (fr) 2006-05-03
JP2007500156A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
US20090306072A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20070004720A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US8431585B2 (en) Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20070099918A1 (en) Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
US20030158196A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
CA2667543A1 (fr) Nouvelles compositions pharmaceutiques pour le traitement de troubles respiratoires et gastro-intestinaux
KR20080067643A (ko) 호흡기 장애의 치료를 위한 신규한 약제학적 병용제제
CA2543649A1 (fr) Utilisation d'inhibiteurs de tyrosine-kinase pour traiter des processus inflammatoires
US20050059661A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
JP2009523700A (ja) 慢性鼻副鼻腔炎の治療のためのチロシンキナーゼ抑制剤の使用
CA2533752A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires
AU2003206881B2 (en) New medicinal compositions on the basis of anticholinergic agents and EGFR kinase inhibitors
DE102005005505A1 (de) Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung der chronischen Rhinosinusitis
JP2004511542A (ja) 煙の吸入の治療のためのｐ３８阻害剤の使用
US20120041043A1 (en) Sulfonamide Compounds for the Treatment of Respiratory Disorders
WO2023003468A1 (fr) Nouveaux inhibiteurs de l'histone désacétylase (hdac), procédés, compositions et utilisations s'y rapportant
WILSON et al. Proceedings ofthe British Thoracic Society
JPWO2006118169A1 (ja) Ｐｇｄ２受容体アンタゴニストおよびロイコトリエン受容体アンタゴニストからなる抗喘息薬

Legal Events

Date Code Title Description
FZDE Dead